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Evaluation of Rasburicase Utilization for Hyperuricemia
Rachael L. Gerstein, PharmD; Arun Mancheril, PharmD, BCPS; Hope Kincaid, MPH, CPH; Kristin Held Wheatley, PharmD, BCOP
Lehigh Valley Health Network, Allentown, PA
Background
•  Tumor lysis syndrome (TLS) is an oncologic 
emergency that occurs due to a rapid lysis of 
malignant cells that overwhelms the normal 
homeostatic mechanisms leading to hyperuricemia, 
hyperkalemia, hyperphosphatemia, hypocalcemia, 
and uremia
•  Treatment of TLS involves hydration, correction 
of electrolyte abnormalities, administration of a 
xanthine oxidase inhibitor, administration of 
rasburicase, and possibly dialysis
•  Rasburicase (Elitek®) is an Aspergillus-derived 
recombinant urate oxidase approved for 
treatment of hyperuricemia associated with 
malignancy
•  Due to its significant cost, rasburicase should 
be reserved for patients who are at high risk 
for TLS, including high tumor burden, 
treatment with highly active cell-cycle specific 
chemotherapy agents, pre-existing renal 
dysfunction, or uric acid ≥ 8 mg/dL
•  As a cost savings initiative, numerous studies 
have shown successful reduction of uric acid 
with single-dose rasburicase leading to dosing 
recommendations being expanded to include 
single-dose rasburicase of 3mg or 6mg
Objectives
Primary Objective 
•  Calculate percentage of patients who received 
rasburicase that met high-risk criteria for TLS
Secondary Objectives
•  Calculate percentage of patients who received allopurinol 
prior to rasburicase
•  Calculate percentage of patients who achieved uric acid 
≤ 8 mg/dL 24 hours after a single dose of rasburicase 
stratified by rasburicase dose (3mg or 6mg)
•  Evaluate cost savings of utilizing single-dose of rasburicase 
3mg for patients that qualified for this dose
Methods 
•  A retrospective chart review was conducted for 
inpatients 18 years and older that received rasburicase 
at Lehigh Valley Hospital-Cedar Crest and Muhlenberg 
campuses from January 1, 2017 to August 19, 2019
•  High-risk criteria for TLS was defined as patients with an 
oncology diagnosis and EITHER a lactate dehydrogenase 
(LD) > 2 times the upper limit of normal OR WBC  
> 25 K/uL, AND uric acid ≥ 8 mg/dL or 25% increase 
from baseline
•  Statistical analysis included descriptive statistics for 
demographics and baseline characteristics, calculated 
frequencies and percentages for categorical variables, 
and calculated average with standard deviation for 
normally distributed continuous variables
Results 
Patient Characteristics (N=121) N(%)
Male 79 (65.3)






Unknown 113 (93.4) 
Hemodialysis Required 20 (16.5)
Rasburicase Dose (N=155)
3mg Dose 53 (34.2)
6mg Dose 99 (63.9)
Other Dose* 3 (1.9)
Average ±  
Standard Deviation
Age (years) 66.0 ± 12.1
Weight (kg) 90.5 ± 22.8
Laboratory Concentrations prior to Rasburicase
WBC (K/uL) 41.2 ± 67.4  
LD (unit/L) 1253.5 ± 1590.8
Potassium (mmol/L) 4.4 ± 0.8
Phosphorus (mg/dL) 4.6 ± 1.6
Calcium (mg/dL) 8.4 ± 1.1
Uric acid (mg/dL) 11.3 ± 4.2
Serum creatinine (mg/dL) 2.4 ± 1.8
* Other Doses: 1.5mg, 9mg, 12mg
Conclusion
•  Out of all patients that received rasburicase,  
64 patients met high-risk criteria for TLS with 
35.9% meeting WBC criteria and 84.4% 
meeting LD criteria
•  Total of 75.2% of patients achieved uric acid  
≤ 8 mg/dL 24 hours after a single dose of 
rasburicase
•  There were 50 patients that received 6mg of 
rasburicase that qualified for a lower dose of 
3mg due to a uric acid ≤ 12 mg/dL at time of 
confirmed TLS associated with a potential cost 
savings of $104,055
•  Further discussion is warranted into implementing 
ordering criteria for rasburicase due to the 
potential cost savings of $207,069.45 for 
patients that did not meet the specified criteria
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Potential Cost Savings of Implementing Rasburicase 












3mg and 6mg doses
Lower 3mg dose 
implemented
Co
st
 ($
)
$427,666.05
$323,611.05
